Medicaid Policies To Contain Psychiatric Drug Costs
- 1 March 2005
- journal article
- review article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 24 (2) , 536-544
- https://doi.org/10.1377/hlthaff.24.2.536
Abstract
This study reviews Medicaid policies to restrict access to psychiatric medications. Policies on prior authorization, preferred drug lists, limitations on the number of prescriptions, fail-first requirements, and use of generics are reviewed. All states apply one or more of those policies to medications for mental illness, and many apply several. A large number of states have legislated exemptions from those policies for certain medications, particularly antipsychotics and antidepressants. Other psychiatric medications are less well protected. Some states appear to restrict access severely. Questions have been raised as to whether these policies actually save money in the long term.Keywords
This publication has 5 references indexed in Scilit:
- Benefits And Risks Of Increasing Restrictions On Access To Costly Drugs In MedicaidHealth Affairs, 2004
- Physicians’ Views Of Formularies: Implications For Medicare Drug Benefit DesignHealth Affairs, 2004
- Managing Psychotropic Drug Costs: Will Formularies Work?Health Affairs, 2003
- A Meta-analysis of the Efficacy of Second-Generation AntipsychoticsArchives of General Psychiatry, 2003
- Effects of Limiting Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with SchizophreniaNew England Journal of Medicine, 1994